Vaheedha S
Research Subjects
Vaheedha S has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amarnath Reganti1 shared publication
- Devika P Jeeragyal1 shared publication
- Kiran Velukuri
Apollo college of Physiotherapy, The Apollo University
1 shared publication - Neelima Grandhe
Department of Pharmaceutical Analysis, Sri Venkateswara College of Pharmacy (Autonomous), Chittoor, Andhra Pradesh, India
1 shared publication - Praveen Hoogar
School of Social Science, The Apollo University, Chittoor, Andhra Pradesh, 517127
1 shared publication - Sreerama Rajasekhar
Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology Vellore – 632 014, Tamil Nadu India
1 shared publication
Latest Publications
- 23 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
Purpose: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance. Methods: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies. Results: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin–CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies. Conclusion: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.
- 23 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
Purpose: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance. Methods: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies. Results: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin–CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies. Conclusion: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.